endo-BCN-O-PNB|CAS 1263166-91-1|DC Chemicals

Cas No.:	1263166-91-1
Chemical Name:	endo-BCN-O-PNB
Synonyms:	((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl 4-nitrophenyl carbonate;endo BCN-O-PNB;[(1R,8S)-9-bicyclo[6.1.0]non-4-ynyl]methyl (4-nitrophenyl) carbonate;endo BCN-O-PNP;BCN-PNP (ENDO);endo-BCN-PNB ester;endo BCN - active ester (p-NPE);endo BCN - active ester (p-NPC);endo-BCN-PNP-carbonate;endo-BCN-O-PNB;rel-((1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-yl)methyl (4-nitrophenyl) carbonate;DA-52892;AKOS040756605;BS-44511;CS-0118072;1263166-91-1;BS-44693;((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl4-nitrophenylcarbonate;BCN-OPNP;exo BCN-O-PNB;EN300-7396847;Carbonic acid, (1alpha,8alpha,9alpha)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 4-nitrophenyl ester;((1R,8S,9r)-bicyclo[610]non-4-yn-9-yl)methyl 4-nitrophenyl carbonate;((1R,8S,9r)-bicyclo[6.1.0]non-4-yn-9-yl)methyl 4-nitrophenyl carbonate;(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 4-nitrophenyl carbonate;Carbonic acid, (1I+/-,8I+/-,9I(2))-bicyclo[6.1.0]non-4-yn-9-ylmethyl 4-nitrophenyl ester;AKOS040743310;BP-20505;((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl (4-nitrophenyl) carbonate;[(1R,8S,9R)-bicyclo[6.1.0]non-4-yn-9-yl]methyl 4-nitrophenyl carbonate;MFCD19705415;HY-43581;HY-133406;CS-0084943;BCN-OPNP, EXO-;1380006-72-3;[(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl]methyl 4-nitrophenyl carbonate;endo-BCN-PNP carbonate;SCHEMBL14981486;AT22141;endo BCN--PNB;AT22143;DA-77391;rel-((1R,8S,9r)-Bicyclo[6.1.0]non-4-yn-9-yl)methyl (4-nitrophenyl) carbonate;DTXSID301135358;XH1576;exo-BCN-PNP carbonate;EN300-7406847
SMILES:	C([C@H]1[C@@]2([H])CCC#CCC[C@@]12[H])OC(=O)OC1C=CC(N(=O)=O)=CC=1
Formula:	C₁₇H₁₇NO₅
M.Wt:	315.320585012436
Purity:	98%
Sotrage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Cat. No.	Product name	Field of application
DC65211	KT-474	KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.
DC39826	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1, is a cereblon degrader.
DC74523	XY-07-35	XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74496	HJM-561	HJM-561 is a potent, selective and orally bioavailable EGFR PROTAC degrader, selectively degrades the EGFR C797S-containing triple mutants Del19/T790M/C797S and L858R/T790M/C797S with DC50 values of 9.2 nM and 5.8 nM, respectively.
DC74494	GNE-0011	GNE-0011 is a monovalent, JQ1-based BRD4 degrader that is not linked to an E3 ligase binder, triggers proteasomal and ubiquitin-dependent selective degradation of BRD4 over BRD2 and BRD3.
DC74479	BSJ-05-037	BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78.
DC72756	JQAD1	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC48434	TD-165	TD165(TD 165) is a PROTAC-based cereblon (CRBN) degrader that degrads Cav1.2α with the DC50 of 20.4 nM, comprising a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
DC46405	ARD-2128	ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
DC46309	Boc-piperazine-benzoic acid	Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128.